Rabeprazole in treatment of acid peptic diseases: Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD)

Digestive Diseases and Sciences

Volumn 43, Issue 5, 1998, Pages 993-1000

  Cloud, M L ^b   Enas, N ^b   Humphries, T J ^a   Bassion, S ^b  

^a EISAI CO LTD   (Japan)

^b NONE

Author keywords

13C urea breath test; Duodenal ulcer; Gastric ulcer; Gastroesophageal reflux; Helicobacter pylori; Rabeprazole

Indexed keywords

GASTRIN; LY 307640; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; UNCLASSIFIED DRUG; UREA;

ADULT; ARGYROPHILIA; ARTICLE; BREATH ANALYSIS; CELL HYPERPLASIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DUODENUM ULCER; ENTEROCHROMAFFIN CELL; EROSIVE GASTRITIS; ESOPHAGITIS; FEMALE; GASTRIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER; TREATMENT OUTCOME; ULCER HEALING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; BREATH TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DUODENAL ULCER; ENZYME INHIBITORS; FEMALE; GASTRINS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON-TRANSLOCATING ATPASES; STOMACH ULCER; TREATMENT OUTCOME;

EID: 0031899196     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018822532736     Document Type: Article

References (27)

1. Physicians Desk Reference, Medical Economics Company, Inc., Montvale, New Jersey, 1996
2. Havu N: Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 35(suppl 1):42-55, 1986
3. McTavish D, Buckley MM, Heel RC: Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 42:138-170, 1991
4. +-ATPase is correlated with the rate of acid-activation of the inhibitor. Biochem Pharmacol 39:661-667, 1990
5. Fujisaki H, Shibata H, Oketani K, Murakami M, Fujimoto M, Wakabayashi T, Yamatsu I, Takeguchi N: Effects of the proton pump inhibitor, E3810, on gastric secretion and gastric and duodenal ulcers or erosions in rats. Drug Invest 3:328-332, 1991
6. Hirai M, Azuma T, Ito S, Kato T, Kohli Y: A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol 30:461-464, 1995
7. Tsuchiya M, Imamura L, Park JB, Kobashi K: Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull 18:1053-1056, 1995
8. Eisai, Inc: Data on file. Eisai, Teaneck, New Jersey.
9. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, Mitchell B, Beveridge BR, Laurence BH, Gibson GG: Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95:903-912, 1988
10. 13C-urea breath test. Am J Gastroenterol 88:1865-1869, 1993
11. Asaka M, Kato M, Kudo M, Meguro T, Kimura T, Miyazaki T, Inoue K: The role of Helicobacter pylori in peptic ulcer disease. Gastroenterol Jpn 28(suppl 5):163-167, 1993
12. Bardhan KD, Dekkers CP, Lam SK, Nowak A, Schaffalitzky de Muckadell OB, Schutze K, Tildesley G, Kler L, Forster JK, Lacey LF, et al: GR122311X (ranitidine bismuth citrate), a new drug for the treatment of duodenal ulcer. Aliment Pharmacol Ther 9:497-506, 1995
13. Beglinger C: Current perspectives in ulcer disease. Ther Umsch 47:681-685, 1990
14. Bell GD, Powell KU: Eradication of Helicobacter pylori and its effect in peptic ulcer disease. Scand J Gastroenterol Suppl 196:7-11, 1993
15. Berstad K, Berstad A: Helicobacter pylori infection in peptic ulcer disease. Scand J Gastroenterol 28:561-567, 1993
16. Fedotin MS: Helicobacter pylori and peptic ulcer disease. Reexamining the therapeutic approach. Postgrad Med 94:38-40, 43-45, 1993
17. Gad A, Hradsky M, Furugard K, Malmodin B: Campylobacter pylori and gastroduodenal ulcer disease. A prospective study in a Swedish population. Scand J Gastroenterol Suppl 167:81-85, 1989
18. O'Connor HJ: The role of Helicobacter pylori in peptic ulcer disease. Scand J Gastroenterol Suppl 201:11-15, 1994
19. Rune S: Helicobacter pylori, peptic ulcer disease and inhibition of gastric acid secretion. Digestion 51 (suppl 1):11-16, 1992
20. Vaira D, Miglioli M, Mule P, Holton J, Menegatti M, Vergura M, Biasco G, Conte R, Logan RP, Barbara L: Prevalence of peptic ulcer in Helicobacter pylori-positive blood donors. Gut 35:309-312, 1994
21. 13C-Urea-Atemtests zum Nachweis von Helicobacter pylori. Schweiz Med Wochenschr 121:764-766, 1991
22. Klein PD, Graham DY: Minimum analysis requirements for the detection of Helicobacter pylori infection by the 13C-urea breath test. Am J Gastroenterol 88:1865-1869, 1993
23. Savarino V, Mela GS, Zentlin P, Cutela P, Mele M, Vigneri S, Celle G: Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy. Dig Dis Sci 39:161-168, 1994
24. Leiete LP, Johnson BT, Just RJ, Castell DO: Persistent acid secretion during omeprazole therapy: A study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 91:1527-1531, 1996
25. Cloud ML, Olovich K, Enas N, Bassion S, Humphries T: LY307640 versus placebo in healing erosive, ulcerative reflux esophagitis. Gastroenterology 108:A73, 1995
26. Humphries TJ, Cloud ML, Enas N, Bassion S, McNamara M, Mele M, Vigneri S, Celle G, The U.S. Raberprazole Gastric Ulcer Study Group: Rabeprazole (E3810, LY307640) achieves high rates of healing in active gastric ulcer. Gastroenterology 110:A138, 1996
27. Cloud ML, Olovich K, Enas N, Bassion S, Humphries T: LY307640 versus placebo in healing duodenal ulcers. Gastroenterology 108:A73, 1995